This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Carboplatin parenteral

Updated 2 Feb 2023 | Platinum Compounds


Parenteral formulations of carboplatin.

Drugs List

  • carboplatin 150mg/15ml concentrate for solution for infusion
  • carboplatin 450mg/45ml concentrate for solution for infusion
  • carboplatin 50mg/5ml concentrate for solution for infusion
  • carboplatin 600mg/60ml concentrate for solution for infusion
  • Therapeutic Indications


    Small cell lung cancer
    Treatment of carcinoma of the ovary

    Ovarian carcinoma of epithelial origin as first line therapy or second line therapy after other treatments have failed.

    Small cell carcinoma of the lung.

    Unlicensed Uses

    Paediatric malignancies

    In paediatric patients:
    Germ cell tumours, high risk Wilms' tumour, low-grade gliomas, neuroectodermal tumours, retinoblastoma, rhabdomyosarcoma (metastatic and non-metastatic disease), soft-tissue sarcomas, stage 4 neuroblastoma and some liver tumours.


    Local cancer network protocols for the relevant indication should be consulted.

    Due to the complexity and specialist nature of dosage regimens for the treatment of malignant disease, specific dosing information on this agent is not included.
    Doses may vary significantly if this agent is used as monotherapy or different combinations.
    When using this agent, specialist literature, national guidelines, cancer network protocols and Trust chemotherapy protocols should be consulted.

    Patients with Renal Impairment

    It is recommended that the use of a formula, such as the Calvert formula, is used to calculate dose as it accounts for renal function.


    Dilute and administer by intravenous infusion.


    Neoplasm with increased bleeding risk
    Renal impairment - creatinine clearance below 20ml/minute
    Severe myelosuppression

    Precautions and Warnings

    Children under 18 years
    Patients over 65 years
    Hepatic impairment
    Renal impairment - creatinine clearance below 60ml/minute

    Administration of live vaccines is not recommended
    Advise ability to drive/operate machinery may be affected by side effects
    Give pre-treatment counselling and consideration of sperm cryopreservation
    Maintain adequate hydration of patient prior / during treatment
    For intravenous use only
    May interact with aluminium metal - avoid contact with aluminium hardware
    Staff: Not to be handled by pregnant staff
    Treatment to be administered by or under supervision of specialist
    Perform blood counts before and at weekly intervals during treatment
    Assess hearing regularly
    Monitor for signs and symptoms of allergic reaction
    Monitor for signs of neurological toxicity
    Monitor for signs of portal hypertension
    Monitor hepatic function regularly
    Monitor patients for signs of tumour lysis syndrome
    Monitor renal function regularly
    Monitor serum electrolytes in patients with renal impairment
    Antibody response to non-live vaccines may be diminished
    Consider the use of anti-emetics before and during therapy
    Consider dose reduction/ discontinuation if moderate hepatic changes occur
    Discontinue at first signs of microangiopathic haemolytic anaemia
    Discontinue if posterior reversible encephalopathy syndrome (PRES) develops
    Discontinue or reduce dose if renal impairment worsens
    Suspend treatment if neutrophil count is less than 2,000 per cubic mm
    Suspend treatment if platelet count is less than 100,000 per cubic mm
    Combination myelosuppressive drug therapy may necessitate dose adjustment
    Treatment courses should not be repeated more frequently than every 4 weeks
    Male & female: Contraception required during & for 6 months after treatment

    Myelosuppression is the dose limiting toxic reaction of carboplatin, it is closely related to the renal clearance of the drug. In patients with impaired renal function or who are receiving concomitant therapy with nephrotoxic drugs, myelosuppression, especially thrombocytopenia, may be more severe and prolonged. Initial dose should be reduced by 20 to 25% in patients with risk factors such as myelosuppressive therapy and/or poor performance status (e.g. ECOG-Zubrod performance status of 2-4 or Karnofsky performance status below 80).

    Elderly patients with combination therapy of carboplatin and cyclophosphamide, are more likely to develop severe thrombocytopenia than younger patients. Consider renal function when determining dose in this population.

    Posterior reversible encephalopathy syndrome (PRES) has been reported in some patients treated with this agent. If patients present with symptoms indicating PRES such as headache, altered mental state, seizures and visual disturbances, an MRI should be performed. If PRES is diagnosed, treatment should be discontinued and adequate blood pressure and seizure control administration is advisable. The safety of reinstating treatment in patients previously experiencing PRES is unknown.

    Pregnancy and Lactation


    Carboplatin is contraindicated during pregnancy.

    It is not known if carboplatin crosses the placenta, but due to the potential for serious adverse reactions the manufacturer recommends that carboplatin is not used during pregnancy.

    Animal studies have shown reproductive toxicity, and has shown dose-related embryo toxicity and teratogenicity in one animal species.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14-17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Carboplatin is contraindicated in breastfeeding.

    It is not known if carboplatin is excreted in human breast milk. The manufacturer recommends that carboplatin is not used during breastfeeding.

    Lactmed suggests that it may be possible for a woman treated with carboplatin to breastfeed safely during intermittent therapy by using an appropriate period of breastfeeding abstinence, but did not suggest a duration for this period.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Abdominal pain
    Abnormal liver function tests
    Allergic reaction
    Anaphylactic shock
    Anaphylactoid reaction
    Blood urea increased
    Cardiac failure
    Cardiovascular disturbances
    Cerebrovascular accident
    Cerebrovascular disorders
    Chest tightness
    Decrease in creatinine clearance
    Electrolyte disturbances
    Erythema at injection site
    Erythematous rash
    Facial flushing
    Facial oedema
    Febrile neutropenia
    Haemolytic uraemic syndrome
    Hearing disturbances
    Hearing loss
    Impaired fertility
    Increase in alkaline phosphatase
    Increase in aminotransferase level
    Increase in blood urea nitrogen
    Increased uric acid level
    Influenza-like syndrome
    Injection site reactions
    Interstitial lung disease
    Local reaction at injection site
    Loss of deep tendon reflexes
    Loss of vision(transient)
    Musculoskeletal disturbances
    Necrosis (injection site)
    Nervous system effects
    Optic neuritis
    Peripheral neuropathy
    Pulmonary fibrosis
    Reduced granulocyte count
    Renal impairment
    Renal toxicity
    Respiratory disorders
    Reversible posterior leucoencephalopathy syndrome (RPLS)
    Risk of secondary tumours as late sequelae
    Sensory disturbances
    Serum bilirubin increased
    Serum creatinine increased
    Severe hepatic reactions
    Swelling (injection site)
    Taste disturbances
    Thoracic and mediastinal disorders
    Tumour lysis syndrome
    Visual disturbances


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: July 2018

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.

    Summary of Product Characteristics: Carboplatin 10mg/ml concentration for solution for infusion. Accord Healthcare Ltd. Revised November 2012.
    Summary of Product Characteristics: Carboplatin 10mg/ml concentration for solution for infusion. Hospira UK Ltd. Revised May 2017.
    Summary of Product Characteristics: Carboplatin 10mg/ml concentration for solution for infusion. Teva UK Ltd. Revised February 2017.

    NICE Evidence Services Available at: Last accessed: 19th July 2018

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.